Research Study

Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects With mCRPC
Principal Investigator 
Bernhard Eigl

Overview

Body Locations and Systems 
Prostate Cancer
Disorders and Conditions 
Cancers
ClinicalTrials.gov# 
NCT03792841
Status 
Recruiting
Study Start/End 
Jun 1, 2020 to Dec 31, 2023
Name/Title 
Lauren Hull
Phone 
604-829-7655 ext.67-8112
Purpose of Study 

The purpose of this study is to evaluate the safety and tolerability of AMG 160; a half-life extended (HLE) bispecific T-cell engager (BiTE®) antibody construct, alone and in combination with pembrolizumab in subjects with metastatic castration-resistant prostate cancer.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.